Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Cost of Goods Sold

Other segment segments

Similar metrics at other companies

LQD

LQDAProduct — Cost of Goods Sold

$11.08M—

OPKPharmaceutical — Cost of Goods Sold

$22.3M-2.3%

RHLDGpgi Holdings Llc — Cost of Goods Sold

$50.46M+0.2%

CDREProducts — Cost of Goods Sold

$84.46M+34.9%

ECLGlobal Healthcare And Life Sciences — Cost of Goods Sold

$108M+10.9%

WINAProduct — Cost of Goods Sold

$618.5K-30.4%

Questions, answered.

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold?

Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — cost of goods sold of $1.23M in Q1 2026.

How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold changed year-over-year?

Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold increased by 37.2% year-over-year, from $894K to $1.23M.

What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold?

Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — cost of goods sold has grown at a 8.1% compound annual growth rate (CAGR), from $4.64M to $5.42M.

What does gyre pharmaceuticals — cost of goods sold mean?

This reflects the direct costs attributable to the production and delivery of the pharmaceutical products sold by the segment. Monitoring this metric is essential for evaluating the segment's production efficiency and gross margin potential.